Entecavir surprise

New England Journal of Medicine

Volumn 356, Issue 25, 2007, Pages 2641-2643

  Hirsch, Martin S ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Partners AIDS Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR;

ANTIVIRAL ACTIVITY; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL;

EID: 34250750123     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe078045     Document Type: Editorial

References (11)

1. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006;194:11-9.
2. Levy V, Grant RM. Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls. Clin Infect Dis 2006;43:904-10.
3. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991;163:1138-40.
4. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-6.
5. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Rockville, MD: Department of Health and Human Services, October 10, 2006. (Accessed June 1, 2007, at http://AIDSinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf.)
6. Sheldon JA, Corral A, Rodes B, et al. Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS 2005;19:2036-8.
7. McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 2007;356:2614-21.
8. Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997;41:1444-8.
9. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Entecavir in hepatitis B virus (HBV)/HIV co-infected patients: supplement to the Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents - October 10, 2006. Rockville, MD: Department of Health and Human Services, April 30, 2007. (Accessed June 1, 2007, at http://aidsinfo.nih.gov/ contentfiles/EntecavirInHIV.pdf.)
10. Phillips AN, Gazzard BG, Clumeck N, Losso MH, Lundgren JD. When should antiretroviral therapy for HIV be started? BMJ 2007;334:76-8.
11. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007;44:441-6.